Digestive Diseases
| Ulcerative colitis
Digestive Diseases
Ulcerative colitis
The efficacy of induction treatment with guselkumab in patients with moderately to severely active ulcerative colitis: Phase 3 QUASAR induction study results at week 12 by prior advanced therapy history
book_2
Source:
UEG Week 2023 - Oral session
calendar_today
Published on Medfyle:
November 2023
import_contacts
5
min
In this medfyle
The Phase 3 QUASAR induction study evaluated the efficacy and safety of guselkumab in patients with moderately to severely active UC. These induction study results report guselkumab efficacy outcomes by history of inadequate response, loss of response, or intolerance to advanced therapy.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the UEG Week 2023.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content.
©2023 Infomedica-Medfyle. All rights reserved.
